{"id":"fimasartan-indapamide","safety":{"commonSideEffects":[{"rate":null,"effect":"Dizziness"},{"rate":null,"effect":"Fatigue"},{"rate":null,"effect":"Hyperuricemia"},{"rate":null,"effect":"Hypokalemia"},{"rate":null,"effect":"Headache"}]},"_chembl":{"chemblId":"CHEMBL406","moleculeType":"Small molecule","molecularWeight":"365.84"},"_fixedAt":"2026-03-30T16:37:46.391048","_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Fimasartan is an angiotensin II receptor blocker (ARB) that prevents angiotensin II from binding to AT1 receptors on blood vessels and the heart, causing vasodilation and reduced blood pressure. Indapamide is a thiazide-like diuretic that inhibits sodium reabsorption in the distal convoluted tubule, promoting sodium and water excretion and reducing blood volume. The combination provides complementary antihypertensive effects through different mechanisms.","oneSentence":"Fimasartan blocks angiotensin II receptors to lower blood pressure, while indapamide acts as a thiazide-like diuretic to reduce fluid volume and further decrease blood pressure.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:12:35.629Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Essential hypertension"}]},"_fixedFields":["pubmed(1)"],"trialDetails":[{"nctId":"NCT07421414","phase":"PHASE1","title":"A Study to Evaluate the Pharmacokinetics and the Safety After Administration of BR1015-A and Co-administration of BR1015-3 and BR1015-2 Under Fed Conditions","status":"NOT_YET_RECRUITING","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2026-04-19","conditions":"Essential Hypertension","enrollment":48},{"nctId":"NCT05878561","phase":"PHASE3","title":"A Study to Evaluate the Efficacy and Safety of BR1015 Combination Therapy","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2022-11-09","conditions":"Essential Hypertension","enrollment":248},{"nctId":"NCT05097794","phase":"PHASE1","title":"A Clinical Trial to Evaluate Drug-drug Interactions and Safety Between \"BR1015-1\" and \"BR1015-2\" in Healthy Volunteers","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2021-08-16","conditions":"Hypertension","enrollment":31},{"nctId":"NCT03246555","phase":"PHASE3","title":"Fimasartan in the Senior Subjects","status":"COMPLETED","sponsor":"Boryung Pharmaceutical Co., Ltd","startDate":"2016-07-15","conditions":"The Elderly (≥ 70 Years) With Essential Hypertension","enrollment":241}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"recentPublications":[{"date":"2021 Oct","pmid":"34503866","title":"A Randomized, Double-blind, Active-controlled, Two Parallel-Group, Optional Titration, Multicenter, Phase IIIb Study to Evaluate the Efficacy and Safety of Fimasartan Versus Perindopril Monotherapy With and Without a Diuretic Combination in Elderly Patients With Essential Hypertension.","journal":"Clinical therapeutics"}],"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["I : BR1015-3 + BR1015-2, II : BR1015-1 + BR1015-2","I : BR1015-3 + BR1015-4, II : BR1015-1 + BR1015-4"],"phase":"phase_3","status":"active","brandName":"Fimasartan + Indapamide","genericName":"Fimasartan + Indapamide","companyName":"Boryung Pharmaceutical Co., Ltd","companyId":"boryung-pharmaceutical-co-ltd","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Fimasartan blocks angiotensin II receptors to lower blood pressure, while indapamide acts as a thiazide-like diuretic to reduce fluid volume and further decrease blood pressure. Used for Essential hypertension.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}